SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS (Clinical Outcomes ...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 32nd International Symposium on ALS/MND ...
In the spring of 2023, Cytokinetics announced a pivot. Following the failure of ALS drug candidate reldesemtiv in a late-stage trial, the California-based biotech said it would focus its resources on ...
SOUTH SAN FRANCISCO, Calif., and WASHINGTON, May 27, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in ...
COURAGE-ALS OLE is an open-label extension clinical study of reldesemtiv in people with ALS who have completed participation in COURAGE-ALS. Following enrollment in COURAGE-ALS OLE, participants will ...
Cytokinetics will stop further testing of its experimental amyotrophic lateral sclerosis drug after an early look at the data found it was unlikely to succeed. The result comes four years after the ...
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results